Welcome to European Tribune. It's gone a bit quiet around here these days, but it's still going.
Regeneron to stop enrolling very sick COVID-19 patients in antibody trial
The recommendation was based on a potential safety signal and an unfavorable risk-benefit profile at this time, the company said. Rival Eli Lilly & Co stopped enrolling such patients based on a similar suggestion earlier this week.
Regeneron shares were down nearly 3% at $540.87 [?!!].
Mission accomplished. Wed Oct 7th, 2020
by Cat on Sat Oct 31st, 2020 at 12:20:20 PM EST
[ Parent ]

Others have rated this comment as follows:


Occasional Series